• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Lilly Unveils Q4 2025 Financial Updates, Offers 2026 Outlook

    PR NEWSWIRE

    Lilly Eyes Pipeline in a Product as GLP-1s Move Into I&I

    BIOSPACE

    Lilly Drops 3 Clinical Programs, Including Prevail Gene Therapy

    FIERCE BIOTECH

    Obesity Market Sales Tightens as Novo & Lilly Enter New Era

    REUTERS

    Lilly Drafts Plan For Last Of 4 New US Drug Manufacturing Plants

    FIERCE PHARMA

    Roche Plans To Go Toe-To-Toe With Novo, Lilly In Obesity

    BIOSPACE

    Repertoire, Lilly Partner on Autoimmune Diseases

    PR NEWSWIRE

    FOIA Lawsuit Targets Trump MFN Pricing Deals With Lilly, Pfizer

    FIERCE PHARMA

    Lilly Pens $1.1B Pact To Work On Hearing Loss Gene Editing Med

    PRESS RELEASE

    Lilly Refocuses Obesity Conversation On Health In Short Film

    FIERCE PHARMA

    Wegovy Pill Launch Wows With Strong Early Uptake: Analysts

    FIERCE PHARMA

    Lilly Sets Date For Q4 2025 Financial Results Call

    PR NEWSWIRE

    Biocom Unveils Keynote Panel With Abbvie, Amgen, Eli Lilly Heads

    BUSINESSWIRE

    Biohaven Prepares To Challenge Lilly After Tough 2025

    BIOSPACE

    FDA Grants Breakthrough Designation to Lilly`s Sofetabart

    PR NEWSWIRE

    4 Next-Gen Candidates That Could Form the Future of Alzheimer

    BIOSPACE

    Four Next-Gen Candidates Shape Alzheimer`s Future

    BIOSPACE

    FDA Delays Decision On Lilly`s Obesity Drug Orforglipron

    REUTERS

    Compounder Sues Lilly, Novo, Claims Coordinated Crackdown

    BIOSPACE

    Lilly Strategizes For Dominance In Evolving Obesity Market

    BIOSPACE

    Strive Pharmacy Sues Eli Lilly and Novo Nordisk

    PR NEWSWIRE

    Lilly Endowment Grants Wesleyan Impact Partners $5M

    PHARMIWEB

    AbbVie, Amgen, Lilly Urge FDA to Update Post-Approval Rules

    BIOSPACE

    JPM26 Day 1: Obesity Front-And-Center, Q4 Sales Beats

    BIOSPACE

    US FDA Requests Removal of Suicide Warnings From Weight-loss Drug

    REUTERS

    Recludix Pharma Secures Funds For Novel SH2 Domain Inhibitors

    GLOBENEWSWIRE

    Bison Leads $33.5M Series B for Juvena`s Regenerative Pipeline

    BUSINESSWIRE

    Healthdyne Supports Obesity Treatment Access With New Benefit

    PR NEWSWIRE

    JPM26, Day 1: Updates From Lilly, Takeda, Novartis And Sofinnova

    FIERCE BIOTECH

    Lilly, Nvidia form new AI co-innovation lab with $1B investment

    FIERCE BIOTECH

    Tempus Achieves Record Total Contract Value Exceeding $1.1 B

    BUSINESSWIRE

    Abivax shares soar 23% as media report reignites M&A Chatters

    REUTERS

    Schrödinger Teams Up With Lilly To Launch Tunelab Platform

    PHARMIWEB

    Chai Discovery Collaborates With Eli Lilly To Speed Up Biologics

    BUSINESSWIRE

    Lilly Partners With Revvity To Enhance AI Drug Discovery Models

    PHARMIWEB

    Vida Ventures Applauds Aktis Oncology`s Public Market Debut

    BUSINESSWIRE

    ProQR Announces AX-0810 Phase 1 Data and 2026 Candidate

    GLOBENEWSWIRE

    Lilly touts Zepbound-Taltz combo in patients with obesity, PsA

    PR NEWSWIRE

    BigHat Biosciences Partners With Eli Lilly on AI Biologics

    PHARMIWEB

    Lilly, J&J Top Clarivate`s 2026 Drugs to Watch

    FIERCE PHARMA

    Indupro Nabs 2nd Big Pharma Deal With $950M Lilly Pact

    BUSINESSWIRE

    Lilly Acquires Ventyx Biosciences For Advancing Oral Therapies

    PR NEWSWIRE

    Lilly Returns To Nimbus In $1.3B Deal To Create Oral Obesity Med

    BUSINESSWIRE

    Lilly in talks to buy Ventyx Biosciences for more than $1B

    REUTERS

    Lilly Targets $94B Revenue With Oral Obesity Drug By 2026

    BIOSPACE

    Novo and Lilly Cut Prices of Weight-Loss Drugs in China

    REUTERS

    Intense Rivalry Between Lilly And Novo Opens Up India

    ECONOMICTIMES

    MEDI&GENE Partners With Lilly To Advance Obesity Therapeutics

    PR NEWSWIRE

    Eli Lilly Re-Elects Nobel Laureate Carolyn Bertozzi To Board

    INDPHARMAPOST

    Form Health Simplifies GLP-1 Coverage, Transparent Pricing

    BUSINESSWIRE

    Lilly To Participate In J.P. Morgan Healthcare Conference

    PR NEWSWIRE

    Lilly`s Inluriyo Shows Reinforced Efficacy in Breast Cancer

    PR NEWSWIRE

    Lilly Shifts Oral SERD Hopes To Its Largest Oncology Trial Ever

    FIERCE PHARMA

    Lilly`s obesity triple threat tops phase 3 efficacy forecasts

    PR NEWSWIRE

    Lilly`s Jaypirca Boosts Progression-Free Survival By 80%

    PR NEWSWIRE

    Lilly, Adverum Complete Tender Offer & Acquisition

    PR NEWSWIRE

    Why Lilly Is Betting On 2nd-Line CLL Despite 1St-Line Wins

    FIERCE PHARMA

    Lilly Selects Alabama Site as Location for $6 B API Facility

    FIERCE PHARMA

    Lilly looks to become innovation ‘backbone,’ exec says

    FIERCE BIOTECH

    Lilly declares first-quarter 2026 dividend

    PR NEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.